A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma

Published:2008-01-03 Issue:4 Volume:62 Page:673-678
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Reni M.,Berardi R.,Mambrini A.,Pasetto L.,Cereda S.,Ferrari V. D.,Cascinu S.,Cantore M.,Mazza E.,Grisanti S.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-007-0653-y.pdf

Reference26 articles.

1. Burris III HA, Moore MJ, Andersen J et al (1997) Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

2. Reni M, Cordio S, Milandri C et al (2005) Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: a phase III trial. Lancet Oncol 6:369–376

3. Cantore M, Fiorentini G, Luppi G et al (2004) Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective randomized phase III trial of the italian society for integrated locoregional therapy in oncology. J Chemother 16:34–39

4. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB III (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270–3275

5. Rocha Lima CMS, Green MR, Rotche R et al (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776–3783

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel;Investigational New Drugs;2020-10-23

2. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients;Journal of the Formosan Medical Association;2020-01

3. Prognostic factors in advanced pancreatic cancer patients receiving second-line chemotherapy: a single institution experience;Translational Cancer Research;2018-10

4. Significance and Prevalence of Haziness Surrounding the Hepatic Artery and Celiac Axis on Computed Tomographic Imaging After Pancreaticoduodenectomy;Journal of Computer Assisted Tomography;2018

5. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer;British Journal of Cancer;2016-06-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3